newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

  • Tvardi Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026, at 12:00 PM PT.
  • The company presentation will discuss new Phase 2 REVERT IPF clinical trial data for its STAT3 inhibitor TTI-101 reported on January 8, 2026.
  • The presented data show encouraging signals regarding fibrosis, inflammatory markers, pulmonary function, STAT3 inhibition, inflammation, fibrosis, TTI-101, and the impact of the drug on these areas.
  • The audio webcast presentation will be accessible on Tvardi's Investors' website with a replay available for approximately 90 days.
  • Tvardi is a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases including hepatocellular carcinoma.
  • The company is currently conducting clinical trials with TTI-101 in hepatocellular carcinoma (NCT05440708) and TTI-109 in healthy volunteers.
  • The press release includes standard forward-looking statements regarding product candidates clinical development regulatory approval financial risks potential delays cash runway intellectual property third-party reliance competitive factors regulatory changes SEC filings risks uncertainties actual results expectations plans intentions benefits market acceptance capital availability and executive retention.